NEW

Getinge, Cook Medical Reach iCast Distribution Agreement

Getinge and Cook Medical have announced an exclusive sales and distribution agreement for the iCast covered stent system.

Endorail Earns FDA 510(k) clearance: Next-generation magnetic balloon technology optimizes colonoscopy procedural outcomes

Endostart, a pioneering medical device company specializing in gastrointestinal endoscopy solutions, HAS announces a major breakthrough with the FDA 510(k) clearance of its flagship product, Endorail. This achievement represents a significant step forward in advancing...

Survey: Nurse Shortage a Leading Threat to Industry

In honor of Certified Nurses Day, health tech company Carta Healthcare®, whose mission is to harness the value of clinical data, today released the results of a survey about the pain points that health care professionals are currently experiencing. The survey also...

Modular Lab Furniture Systems Meet Needs

UniLine Furniture offerings from HEMCO Corp. include base cabinets, wall cabinets, countertops, sinks, fixtures, base tables, mobile work stations, specialty storage cabinets and peg boards.

Diversey Announces MoonBeam3 Effective Against SARS-CoV-2 in Seconds

Diversey, Inc. has received confirmation through third-party testing that MoonBeam3 UV-C disinfection technology is effective in just seconds against SARS-CoV-2, which causes COVID-19.

MoonBeam3 is an ultraviolet-C disinfection device that adds assurance beyond manual cleaning and disinfection. This portable, powerful solution disinfects quickly, reliably and responsibly. MoonBeam3 is cost-effective and designed for fast disinfection of public and high-risk areas. The system offers three individually adjustable arms that can be positioned at almost any angle, optimizing disinfection energy to allow dosing of both horizontal and vertical surfaces, in just 3 minutes.

MoonBeam3 has undergone third-party testing against several microorganisms including enveloped viruses, small non-enveloped viruses, bacteria and bacterial spores. These tests have demonstrated a significant log reduction in these key pathogens.

Since studies have shown that contamination of environmental surfaces in health care facilities with SARS-CoV-2 viral RNA is widespread, Diversey commissioned third-party testing of MoonBeam3 in the U.S., and has also partnered with the highly respected Fujita Health University in Japan, to test the effectiveness of the MoonBeam3 against SARS-CoV-2. The completed test results from Japan proved that MoonBeam3 was effective against SARS-CoV-2 under a range of conditions with contact times as low as 4 seconds for a 6-log reduction.

This study validates that MoonBeam3 is effective against SARS-CoV-2, the pathogen that causes COVID-19.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X